Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 129. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Untold Lassa fever story: a physician's lived experience859179314
An interactive web-based dashboard to track COVID-19 in real time7589
Estimates of the severity of coronavirus disease 2019: a model-based analysis2632
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study2487
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study2418
Early dynamics of transmission and control of COVID-19: a mathematical modelling study1686
Viral load of SARS-CoV-2 in clinical samples1311
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study1245
Viral dynamics in mild and severe cases of COVID-191216
A minimal common outcome measure set for COVID-19 clinical research1092
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial1023
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study914
A clinical case definition of post-COVID-19 condition by a Delphi consensus914
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics904
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial868
Clinical and virological data of the first cases of COVID-19 in Europe: a case series862
Real estimates of mortality following COVID-19 infection841
COVID-19: combining antiviral and anti-inflammatory treatments828
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study808
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study757
Convalescent plasma as a potential therapy for COVID-19725
Clinical features and management of human monkeypox: a retrospective observational study in the UK703
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study692
Scientific and ethical basis for social-distancing interventions against COVID-19638
Can we contain the COVID-19 outbreak with the same measures as for SARS?628
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study625
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study607
The value of antimicrobial peptides in the age of resistance565
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study557
COVID-19 and multisystem inflammatory syndrome in children and adolescents545
Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study538
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study533
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance529
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study525
Genomic evidence for reinfection with SARS-CoV-2: a case study514
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study509
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study465
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study451
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2449
Asymptomatic cases in a family cluster with SARS-CoV-2 infection442
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study417
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation406
COVID-19 and medical education402
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical 387
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult383
Stigma during the COVID-19 pandemic362
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series345
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study343
The many estimates of the COVID-19 case fatality rate338
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries337
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study333
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study326
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study325
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 317
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison301
Exaggerated risk of transmission of COVID-19 by fomites296
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis291
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial289
The COVID-19 infodemic284
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study280
COVID-19 pneumonia: what has CT taught us?259
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people247
Serology testing in the COVID-19 pandemic response242
Smell and taste dysfunction in patients with COVID-19239
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial232
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England231
Long-term consequences of COVID-19: research needs229
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised227
Scaling up COVID-19 rapid antigen tests: promises and challenges225
Taking the right measures to control COVID-19224
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT223
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression222
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data222
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial218
Covert COVID-19 and false-positive dengue serology in Singapore217
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study215
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study211
Willingness to vaccinate against COVID-19 in Australia211
SARS-CoV-2: virus dynamics and host response209
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial208
Connecting clusters of COVID-19: an epidemiological and serological investigation204
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study201
COVID-19 in Latin America200
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont200
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study199
Open access epidemiological data from the COVID-19 outbreak191
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri191
Intention to vaccinate against COVID-19 in Australia187
Monitoring approaches for health-care workers during the COVID-19 pandemic186
COVID-19 in children: the link in the transmission chain185
The indirect impact of COVID-19 on women181
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study181
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study179
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis178
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden177
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study176
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design176
The important role of serology for COVID-19 control175
Likelihood of survival of coronavirus disease 2019174
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis172
What reinfections mean for COVID-19166
The global incidence and diagnosis of fungal keratitis165
COVID-19 with spontaneous pneumomediastinum164
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial163
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial163
Global shortage of personal protective equipment161
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study161
Baricitinib for COVID-19: a suitable treatment?161
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study160
The first 2019 novel coronavirus case in Nepal159
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity157
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis157
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19155
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later155
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard154
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and 153
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study150
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding149
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study147
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis147
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav145
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis145
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study144
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis144
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5144
Guidelines for pregnant women with suspected SARS-CoV-2 infection139
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis136
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial135
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies132
China's successful control of COVID-19129
0.077630996704102